RT Journal Article
SR Electronic
T1 Implementing a clinical pathway for diagnosing and treating acute HIV infection among key populations attending sexual health clinics in Indonesia: cohort profile of the INTERACT study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.06.24307250
DO 10.1101/2024.06.06.24307250
A1 Irwanto
A1 Kawi, Nurhayati H.
A1 Luis, Hendry
A1 Sihotang, Erik P.
A1 Januraga, Pande Putu
A1 Oktaviani, Margareta
A1 Suwarti
A1 Rahmawati, Dwi P.
A1 Sukmaningrum, Evi
A1 Yanihastuti, Evy
A1 Dijkstra, Maartje
A1 Sanders, Eduard J.
A1 Wignall, F. Stephen
A1 Gedela, Keerti
A1 Hamers, Raph L.
A1 INTERACT Study Group
YR 2024
UL http://medrxiv.org/content/early/2024/06/06/2024.06.06.24307250.abstract
AB Background To reduce the high HIV incidence among key populations in Indonesia, we implemented a clinical pathway for screening, diagnosis and treatment of acute HIV infection (AHI) in sexual health clinics in Jakarta and Bali. This paper presents a cohort profile and analysis of baseline data on the study uptake, diagnostic yield, and estimated AHI prevalence and screening cascade outcomes.Methods We performed a baseline analysis of 1879 individuals who underwent AHI screening at three sexual health clinics in Jakarta and Bali between May and December 2023, comprising a risk-score assessment, fourth-generation antibody/p24 antigen-based rapid diagnostic test (RDT; Abbott Determine HIV Early Detect) and HIV-PCR (Xpert) testing.Results Median age was 27 years (IQR24-31), and 75.4% were male. Men who have sex with men (MSM) accounted for 50.4%, clients of sex workers 20.1%, and sex workers 5.2%. Of 1866 participants tested at study enrolment, 113 (6.1% [113/1866]) had chronic HIV (antibody-positive) and 6 (0.34% [6/1748]) had AEHI. HIV-PCR testing led to a 5.3% (95%CI1.9-11.2) increase in confirmed HIV diagnoses. The number needed to test to detect one AEHI case was 291 (1748/6) overall and 169 (842/5) among MSM. Overall HIV and AHI prevalence was 6.4% (95%CI 5.3-7.6; 119/1866) and 0.34% (95%CI0.12-0.74; 6/1748) overall; and 10.8% (95%CI8.9-13.0; 102/940) and 0.53% (95%CI 0.17-1.2; 5/940) among MSM. The Abbott Determine HIV Early Detect RDT only detected 2 (18.2%) of 11 AEHI cases. 113 (95.0%) newly diagnosed individuals were linked to care and started ART, of whom 75 (66.4%) on the same day and 104 (92.0%) within a week (median 0 days, range 0-93).Conclusion AHI screening, diagnosis and prompt treatment is feasible among high-risk urban MSM in Indonesia. Further evaluations are needed to estimate clinical impact and cost-effectiveness of AHI screening in this setting. The study continues accrual and follow-up, and provides a platform for future immuno-virological, social science, and intervention studies in Indonesia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research is jointly funded by the UK Medical Research Council (MRC) and the Foreign Commonwealth and Development Office (FCDO) under the MRC/FCDO Concordat agreement (grant no. MR/V035304/1). Author (Raph L. Hamers) is supported by the Wellcome Africa Asia Programme Vietnam (106680/Z/14/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the Catholic University of Atma Jaya research ethics committee (0009R/III/PPPE.PM.10.05/10/2022) and the Oxford Tropical Research Ethics Committee (565-22).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe INTERACT Study Group welcome feedback and ideas, including proposals for collaboration on data analyses, new research, or knowledge translation and exchange activities. Requests for data sharing can be made by submission of a study concept to the INTERACT Study Group for evaluation of the scientific value, relevance, design, feasibility, and overlap with existing projects. For more information, please contact the principal investigators: I (irwanto{at}atmajaya.ac.id), KG (k.gedela{at}nhs.net) or RLH (rhamers{at}oucru.org).